NBIX as of Oct 31 · 15:34 ET

NBIXNasdaqBiological Products, (No Diagnostic Substances)

Neurocrine Biosciences Inc · Brief

Next report

2 days

Nov 2 · after closeconfirmedQ3 FY26

Earnings

Expected move

Inputs

±7.5%implied · report alone

135.16157.04

straddle ±8.7%

spot 146.10exp Nov 20ATM strike 145ATM straddle 14.95IV 54%

Oct 30 closereport share · term structure

Expected move

Inputs

Implied vs realized

8 reportsHistory

—≥ implied

Oct 30 '24—▲+7.01%—

Feb 6 '25—▼−18.53%—

May 5 '25—▲+8.36%—

Jul 30 '25—▼−6.24%—

Oct 28 '25—▼−6.35%—

Feb 11 '26—▼−10.43%—

Q1 FY26—▲+8.86%—

Q2 FY26—▼−10.08%—

quarterimplied−20%0+20%realized×

Q2 FY26—▼−10.08%—

Q1 FY26—▲+8.86%—

Feb '26—▼−10.43%—

Oct '25—▼−6.35%—

Jul '25—▼−6.24%—

May '25—▲+8.36%—

2 older reports

Feb '25—▼−18.53%—

Oct '24—▲+7.01%—

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 2 report · confirmed

Bull2 of 3

781managers reporting a position in the latest quarterly filings13F · Jun 30 '26

62managers whose positions make up four fifths of the reported value13F · Jun 30 '26

Bear2

5 of 24of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26

−0.93%change in shares held by the ten largest reporting managers over the latest quarter13F · Jun 30 '26

AI captions · Sep 16 '26once per report · top 2 per case

Linked exposure

NBIX report session

Suppliers 2

VYGRVoyager Therapeutics×0.59 XENEXenon Pharmaceuticals×0.48

× = co-movement · max 500dSource: SEC filings · market data

Latest changes

30 daysAll changes

Oct 19impliedImplied move: ±8.4% into Nov 2 earnings (Oct 19 close).Source

Oct 12report dateEarnings date confirmed: Nov 2, after close.Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.